Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: Results of the randomized Intra-Co-EpoMI trial

Archives of Cardiovascular Diseases

Volumn 106, Issue 3, 2013, Pages 135-145

  Roubille, François ^a   Micheau, Antoine ^b   Combes, Stéphane ^c   Thibaut, Séverine ^b   Souteyrand, Géraud ^d   Cayla, Guillaume ^e   Bonello, Laurent ^f,g   Lesavre, Nathalie ^f,g   Sportouch Dukhan, Catherine ^a   Klein, François ^b   Berboucha, Samir ^h   Cade, Stéphane ^e   Cung, Thien Tri ^a   Raczka, Franck ^a   MacIa, Jean Christophe ^a   Gervasoni, Richard ^a   Cransac, Frédéric ^a   Leclercq, Florence ^a   Barrère Lemaire, Stéphanie ^b   Paganelli, Franck ^f   Mottref, Pascal ^d   Vernhet Kovacsik, Hélène ^b   Ovize, Michel ⁱ   Piot, Christophe ^a   more..

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

^c CLINIQUE PASTEUR   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e DEPARTMENT OF NEUROLOGY   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^h Centre Hospitalier Universitaire de Annaba   (Algeria)

ⁱ UNIVERSITÉ LYON 1   (France)

Author keywords

Acute myocardial infarction; Cardioprotection; Darbepoetin; Erythropoietin; Reperfusion injury

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MAGNETIC RESONANCE; COLLATERAL CIRCULATION; CONTROLLED STUDY; DISEASE DURATION; ENZYME RELEASE; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; BIOLOGICAL MARKERS; COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CREATINE KINASE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; FRANCE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876262969     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.12.001     Document Type: Article

References (46)

1. R.J. Burns, R.J. Gibbons, and Q. Yi The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis J Am Coll Cardiol 39 2002 30 36
2. K.A. Reimer, J.E. Lowe, and M.M. Rasmussen The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs Circulation 56 1977 786 794
3. P. Rentrop, and H. Blanke Percutaneous transluminal coronary artery recanalization in evolving myocardial infarction Cardiovasc Intervent Radiol 5 1982 194 196
4. R.B. Jennings, H.M. Sommers, and G.A. Smyth Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog Arch Pathol 70 1960 68 78
5. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
6. Z.Q. Zhao, J.S. Corvera, and M.E. Halkos Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning Am J Physiol Heart Circ Physiol 285 2003 H579 H588
7. C. Piot, P. Croisille, and P. Staat Effect of cyclosporine on reperfusion injury in acute myocardial infarction N Engl J Med 359 2008 473 481
8. P. Staat, G. Rioufol, and C. Piot Postconditioning the human heart Circulation 112 2005 2143 2148
9. C.G. Winearls, D.O. Oliver, and M.J. Pippard Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis Lancet 2 1986 1175 1178
10. L. Calvillo, R. Latini, and J. Kajstura Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci U S A 100 2003 4802 4806
11. C.J. Parsa, A. Matsumoto, and J. Kim A novel protective effect of erythropoietin in the infarcted heart J Clin Invest 112 2003 999 1007
12. A.F. Tramontano, R. Muniyappa, and A.D. Black Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway Biochem Biophys Res Commun 308 2003 990 994
13. E. Gao, M. Boucher, and J.K. Chuprun Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart Am J Physiol Heart Circ Physiol 293 2007 H60 H68
14. C. Toma, D.P. Letts, and M. Tanabe Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion J Mol Cell Cardiol 43 2007 130 136
15. G.L. Wright, P. Hanlon, and K. Amin Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J 18 2004 1031 1033
16. A.J. Ludman, D.M. Yellon, and J. Hasleton Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial Heart 97 2011 1560 1565
17. S.S. Najjar, S.V. Rao, and C. Melloni Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial JAMA 305 2011 1863 1872
18. I. Ott, S. Schulz, and J. Mehilli Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial Circ Cardiovasc Interv 3 2010 408 413
19. T. Ozawa, K. Toba, and H. Suzuki Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction-randomized controlled pilot trial of EPO/AMI-1 study Circ J 74 2010 1415 1423
20. F. Prunier, L. Biere, and M. Gilard Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial Am Heart J 163 2012 200 270
21. N. Taniguchi, T. Nakamura, and T. Sawada Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study Circ J 74 2010 2365 2371
22. A.A. Voors, A.M. Belonje, and F. Zijlstra A single dose of erythropoietin in ST-elevation myocardial infarction Eur Heart J 31 2010 2593 2600
23. D.J. Hausenloy, G. Baxter, and R. Bell Translating novel strategies for cardioprotection: the Hatter workshop recommendations Basic Res Cardiol 105 2010 677 686
24. E. Lipsic, P. van der Meer, and A.A. Voors A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study Cardiovasc Drugs Ther 20 2006 135 141
25. J.T. Ortiz-Perez, S.N. Meyers, and D.C. Lee Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging Eur Heart J 28 2007 1750 1758
26. W.J. Rogers, E.L. Alderman, and B.R. Chaitman Bypass angioplasty revascularization investigation (BARI): baseline clinical and angiographic data Am J Cardiol 75 1995 9C 17C
27. Y. Asaumi, Y. Kagaya, and M. Takeda Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice Circulation 115 2007 2022 2032
28. D. Burger, M. Lei, and N. Geoghegan-Morphet Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase Cardiovasc Res 72 2006 51 59
29. D.E. Burger, F.L. Xiang, and L. Hammoud Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase J Pharmacol Exp Ther 329 2009 900 907
30. Z. Cai, D.J. Manalo, and G. Wei Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury Circulation 108 2003 79 85
31. F. Fiordaliso, S. Chimenti, and L. Staszewsky A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury Proc Natl Acad Sci U S A 102 2005 2046 2051
32. T. Rui, Q. Feng, and M. Lei Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1 Cardiovasc Res 65 2005 719 727
33. H. Tada, Y. Kagaya, and M. Takeda Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion Cardiovasc Res 71 2006 466 477
34. J.E. Baker, D. Kozik, and A.K. Hsu Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms J Cardiovasc Pharmacol 49 2007 337 345
35. A.J. Bullard, P. Govewalla, and D.M. Yellon Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo Basic Res Cardiol 100 2005 397 403
36. Z. Cai, and G.L. Semenza Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury Circulation 109 2004 2050 2053
37. V. Diwan, R. Kant, and A.S. Jaggi Signal mechanism activated by erythropoietin preconditioning and remote renal preconditioning-induced cardioprotection Mol Cell Biochem 315 2008 195 201
38. C. Moon, M. Krawczyk, and D. Ahn Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats Proc Natl Acad Sci U S A 100 2003 11612 11617
39. P. van der Meer, E. Lipsic, and R.H. Henning Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury Eur J Heart Fail 6 2004 853 859
40. H. Kobayashi, T. Miura, and H. Ishida Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion Clin Exp Pharmacol Physiol 35 2008 812 819
41. C.J. Parsa, J. Kim, and R.U. Riel Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts J Biol Chem 279 2004 20655 20662
42. P. Rafiee, Y. Shi, and J. Su Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways Basic Res Cardiol 100 2005 187 197
43. J.W. Suh, W.Y. Chung, and Y.S. Kim The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention Int J Cardiol 149 2011 216 220
44. C. Berry, P. Kellman, and C. Mancini Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction Circ Cardiovasc Imaging 3 2010 527 535
45. F. Thuny, O. Lairez, and F. Roubille Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction J Am Coll Cardiol 59 2012 2175 2181
46. Y. Guo, M.P. Flaherty, and W.J. Wu Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice Basic Res Cardiol 107 2012 288